Pulmonology · 2 h ago
Dupilumab improved spirometric measures in pooled COPD trial analysis
A post hoc analysis of the randomized BOREAS and NOTUS trials included 1,874 patients with COPD and type 2 inflammation. Dupilumab was associated with improvements in several lung-function measures versus placebo, sustained through 52 weeks.
- Pooled analysis included 1,874 randomized patients.
- Pre-bronchodilator FEV1 difference was 83 mL at week 12.
- Lung-function improvements persisted through week 52.
- Post hoc analysis focused on spirometric outcomes.
The post hoc analysis combined data from BOREAS (NCT03930732) and NOTUS (NCT04456673), in which patients with COPD and type 2 inflammation were randomized to dupilumab 300 mg or placebo every two weeks for 52 weeks. The analysis included 938 patients assigned to dupilumab and 936 assigned to placebo and examined spirometric lung-function measures.
At week 12, the least-squares mean difference in pre-bronchodilator FEV1 was 83 mL (95% CI, 53–112; P<.0001) in favor of dupilumab; the difference was sustained through week 52. Dupilumab also improved post-bronchodilator FEV1, pre- and post-bronchodilator FVC, FEV1/FVC, and mid-expiratory flow. Improvements in pre-bronchodilator FEV1 were reported across smoking-status and emphysema subgroups, with larger improvements among patients with higher baseline eosinophil counts or fractional exhaled nitric oxide.
This is a post hoc analysis of two randomized trials and focuses on spirometric outcomes; the supplied abstract does not report effects on exacerbations, symptoms, or other patient-important outcomes. The findings do not by themselves establish a change in clinical practice.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
American Journal of Respiratory and Critical Care Medicine: Dupilumab is associated with improved lung functions in patients with COPD and type 2 inflammation: a post hoc analysis of the BOREAS and NOTUS trials ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.